Clinical Trial Update: Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of durvalumab (MEDI4736) and AZD6738 in relapsed small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• AZD6738 (ceralasertib)
• Durvalumab (durvalumab)

Snippet

Sponsor: Se-Hoon Lee | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED